MASLD — thematic synthesis of patient-reported experience¶
Themes reported in aggregate. Each theme requires at least two independent sources. Nothing here identifies any private individual; where an organisation publishes a personal account, only the theme is carried across. Method and ethics in README.md; sources in sources.md.
Sample sizes are given for every theme, because they are small: the underlying studies range from 16 adolescents to 1,976 adults, and none is population-representative.
T1. The diagnosis arrives sideways, usually from a test done for another reason¶
| Source | Evidence |
|---|---|
| Stine 2024, PMID 38780312 (28 US adults with MASH and fibrosis, one-to-one interviews) | Patients described a long process of misdiagnoses before arriving at MASH |
| NHS, https://www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/, accessed 2026-09-02 | States the condition usually causes no symptoms, that many people have it without realising, and that it is "usually found when you have tests for another reason" |
| Liver Foundation (Australia), https://www.liver.org.au/your-liver/liver-diseases/fatty-liver-disease/, accessed 2026-09-02 | Published patient transcript describes diagnosis reached after a GP noticed abnormal liver blood tests and ordered further tests |
| Duell 2022, PMID 35418240 (AHA scientific statement) | "The majority of patients with NAFLD are unaware of having this serious condition" |
The route to diagnosis is incidental, and the incidental route shapes everything downstream: patients arrive without a framework for the diagnosis, and often after a period in which their symptoms were attributed elsewhere.
T2. The information vacuum after diagnosis¶
| Source | Evidence |
|---|---|
| Stine 2024, PMID 38780312 (n=28) | A lack of clear information provided by clinicians, and limited accessibility to support groups |
| Fouad 2025, PMID 40337974 (n=222 patients, semi-structured written questionnaire) | 71.9% did not know how the disease is diagnosed; 81.1% did not know how it is treated; only 37.8% knew cirrhosis could result and 16.7% knew hepatocellular carcinoma could; 65.8% wanted to learn more |
| Ley 2022, PMID 35442241 (16 adolescents, focus groups) | Comprehension of the diagnosis varied; the authors recommend "ensuring comprehension of diagnosis" as a care-improvement target |
The Fouad figures are the most striking in this layer: two-thirds of patients with the diagnosis could not say how it is diagnosed, four-fifths could not say how it is treated, and two-thirds actively wanted to know. This is not disengagement.
T3. The disease is not experienced as silent¶
| Source | Evidence |
|---|---|
| Doward 2021, PMID 33336323 (23 concept-elicitation interviews, non-cirrhotic NASH) | Fatigue in 18/23, upper-right abdominal pain in 14/23, impaired memory in 13/23, poor sleep quality in 12/23, reduced focus in 11/23 |
| NHS, accessed 2026-09-02 | Lists feeling very tired, feeling generally unwell, and liver pain or discomfort under the right ribs |
| Liver Canada, https://liver.ca/patients-caregivers/liver-diseases/fatty-liver-disease/, accessed 2026-09-02 | Lists fatigue and weakness, upper-right abdominal pain, and loss of appetite among symptoms |
This directly contradicts the standard clinical framing of early MASLD as asymptomatic — a framing repeated in guidance documents and in the AHA statement. Both accounts can be true: the disease has no signs until advanced, while patients asked directly report a consistent symptom cluster. Which account is correct matters for whether patient-reported outcomes belong in registration trials, where they currently do not appear as endpoints (Sena 2023, PMID 36536958).
T4. Weight is the greater concern, and the greater source of stigma¶
| Source | Evidence |
|---|---|
| Younossi 2024, PMID 37984709 (1,976 patients, 23 countries; 825 providers, 25 countries) | 26% reported stigma related to overweight or obesity; only 8% reported stigmatisation or discrimination due to their liver disease |
| Ley 2022, PMID 35442241 (n=16 adolescents) | 62.5% were more concerned about their weight than about NAFLD; the authors suggest harnessing the desire for weight loss as the more salient driver of change |
| Younossi 2025, PMID 39250515 (MAESTRO-NASH HRQL, n=966) | An LDQOL Stigma domain exists and improved by +3.5 points (39% meeting the minimal clinically important difference) in histological responders, with no improvement in placebo or non-responders |
The anti-stigma intervention the field chose was a liver-disease rename. The stigma patients report is predominantly about body weight.
T5. Patients are largely indifferent to the name; clinicians are not¶
| Source | Evidence |
|---|---|
| Younossi 2024, PMID 37984709 | 56–71% of patients were "neither comfortable nor uncomfortable" with NAFLD, FLD, NASH or MAFLD, with no substantial differences between terms; 88% used "fatty liver" at least sometimes; >84% never used "metabolic disease" or "MAFLD". Among providers, 38% thought "fatty" stigmatising, 34% "nonalcoholic", and 42% thought the rename might reduce stigma |
| Fouad 2025, PMID 40337974 (n=222) | 79.7% did not consider "fatty" stigmatising, while 85.1% said including "alcohol" in a condition's name carries stigma |
| Rinella 2023, PMID 37363821 (236 panellists) | 61% of panellists found "nonalcoholic" stigmatising and 66% found "fatty" stigmatising |
Two independent patient surveys agree that "fatty" is not the problem and that the alcohol reference is. The panellist figures sit close to the provider figures and far from the patient figures. The authors of the Fouad survey conclude the change to MASLD "does not seem warranted, at least if the stigma is the main concern" — a minority position, from a single-centre cross-sectional survey, recorded here because the evidence on this specific question is thin.
T6. Diagnosis is often reframed as reversible, and that reframing is what patients remember¶
| Source | Evidence |
|---|---|
| Liver Foundation (Australia), accessed 2026-09-02 | Published patient transcripts centre on being told the condition was reversible with lifestyle change, and on subsequent dietary and exercise change. The organisation's own key points state "For most people, liver damage can be reversed" |
| Liver Canada, accessed 2026-09-02 | States that if detected early, fatty liver disease "can be improved, or even reversed, with lifestyle and nutrition modifications" |
| NHS, accessed 2026-09-02 | States the condition "can usually be treated with healthy lifestyle changes" |
Reversibility is the dominant message in verified patient-facing material, and it is supported: 22.3% of paired-biopsy patients regressed a fibrosis stage spontaneously, and ≥10% weight loss produced fibrosis regression in 45% (wiki/lifestyle-and-weight-loss.md). The tension is that only 30% of a supervised cohort achieved ≥5% weight loss, and pooled MASH resolution across lifestyle studies is 0.12. Patient-facing material communicates the efficacy and not the attainment.
T7. Fear of progression, and the family dimension¶
| Source | Evidence |
|---|---|
| Stine 2024, PMID 38780312 (n=28) | Hispanic patients reported "impact on family/friends" (75%) and "fear of disease progression" (75%) more frequently than other cohorts — described by the authors as the first report of fear of progression in MASH |
| Doward 2021, PMID 33336323 (n=23) | Health-related quality-of-life impacts included reduced quality of relationships, low mood, anxiety and self-consciousness |
| Younossi 2025, PMID 39250515 (n=966) | The CLDQ-NAFLD Worry domain was the one domain that improved with drug treatment overall (+0.21 to +0.24, p<0.05), and improved most in histological responders (+0.46, 41% meeting MCID) |
That "Worry" is the domain that moves first, and moves in everyone on treatment rather than only in responders, is consistent with the interview finding that fear of progression is a substantial part of the burden. It suggests part of what treatment delivers is the relief of being treated.
T8. Disclosure is limited¶
| Source | Evidence |
|---|---|
| Younossi 2024, PMID 37984709 (n=1,976) | 48% had ever disclosed the diagnosis to family or friends |
| Lazarus 2022, PMID 34707258 (global public-health Delphi) | Records that the disease is "largely unknown outside hepatology and gastroenterology" and absent from nearly all national and international non-communicable-disease strategies |
Fewer than half of people with the diagnosis have told anyone. Low disclosure and low public visibility reinforce each other, and both constrain advocacy: a disease affecting a third of adults has, by this layer's count, exactly one verified dedicated patient organisation worldwide.
T9. Structural barriers sit underneath the behavioural advice¶
| Source | Evidence |
|---|---|
| Ley 2022, PMID 35442241 (n=16 adolescents) | 43.8% identified as food insecure; the authors call for interventions to address systemic barriers "to ensure equitable care" |
| Stine 2024, PMID 38780312 (n=28) | Limited accessibility to support groups |
| Global Liver Institute, https://www.globalliver.org/, accessed 2026-09-02 | Runs a "Liver Health is Public Health" initiative explicitly framed around reaching underserved communities, and a dedicated Veterans Health programme |
The universal first-line recommendation in every guideline is dietary change. In the one adolescent study that asked, nearly half the sample was food insecure.
Themes reported by a single source only — recorded, not promoted¶
Per the ethics rules, these are not entered as themes. They are listed so a future sweep can look for corroboration.
- Nausea and vomiting were reported by patients in every interviewed subgroup except White patients carrying the PNPLA3 I148M variant (Stine 2024, PMID 38780312) — a single-study observation with an obvious confounding risk in a 28-person sample.
- Adolescents preferred tailored, personalised recommendations over generic advice, and were more likely to change behaviour when families were supportive (Ley 2022, PMID 35442241).
- Real-time patient feedback was collected on the NAFLD→MAFLD terminology change (Alem 2021, PMID 33497764); the record retrieved is a correspondence item without an abstract, so its findings are not summarised here.
Coverage limits on these themes¶
- Geography. The two largest sources are a multi-country survey weighted 51% to MENA (PMID 37984709) and a single-centre survey (PMID 40337974). A 16-person interview study from Nanjing now supplies East Asian evidence (PMID 42529177), so the earlier US-only statement is obsolete. Nothing was retrieved from sub-Saharan Africa or Latin America, and continental European evidence remains sparse.
- Disease stage. Interview samples are drawn from people who have a diagnosis and are in specialist care. The great majority of people with MASLD are undiagnosed, and their experience is by definition absent.
- Time. No study has compared patient experience before and after the 2023 nomenclature change, which is the one comparison that would test the rename's stated rationale.
- Sample size. T3, T7 and T9 rest on studies of 16–28 people.